09-05-2025
Clarity Pharmaceuticals Ltd. (CU6) Receives a Buy from Bell Potter
In a report released today, John Hester from Bell Potter maintained a Buy rating on Clarity Pharmaceuticals Ltd. (CU6 – Research Report), with a price target of A$5.20.
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Hester covers the Healthcare sector, focusing on stocks such as Polynovo , Mesoblast Limited, and Telix Pharmaceuticals. According to TipRanks, Hester has an average return of 7.4% and a 51.76% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Clarity Pharmaceuticals Ltd. with a A$6.22 average price target.
The company has a one-year high of A$8.98 and a one-year low of A$1.43. Currently, Clarity Pharmaceuticals Ltd. has an average volume of 2.56M.
